What Will Happen to Adma Biologics Inc (NASDAQ:ADMA) Next? The Stock Has Increase in Shorts

June 16, 2018 - By Dolores Ford

ADMA Biologics, Inc. (NASDAQ:ADMA) Logo

Investors sentiment decreased to 2.86 in 2018 Q1. Its down 0.14, from 3 in 2017Q4. It worsened, as 1 investors sold ADMA Biologics, Inc. shares while 6 reduced holdings. 11 funds opened positions while 9 raised stakes. 15.52 million shares or 0.06% less from 15.53 million shares in 2017Q4 were reported.
Northern Corp invested in 29,143 shares or 0% of the stock. 12,890 are held by Citadel Advsr. Iguana Management Limited Liability Corporation holds 1.82% or 600,000 shares. Advisory Network Ltd Liability Corporation accumulated 1,700 shares or 0% of the stock. Consonance Mngmt L P invested in 3.33 million shares. 683 Capital Management Limited owns 805,000 shares. Spark Investment Limited Liability Company accumulated 0.01% or 22,200 shares. Bancshares Of Mellon Corporation reported 19,037 shares stake. Aisling Cap Llc reported 2.96% of its portfolio in ADMA Biologics, Inc. (NASDAQ:ADMA). Millennium Mngmt Ltd Liability invested in 0% or 273,621 shares. Broadfin Capital Ltd Liability Com has 0.52% invested in ADMA Biologics, Inc. (NASDAQ:ADMA) for 720,529 shares. Geode Mgmt Ltd Liability Corporation accumulated 112,000 shares. The United Kingdom-based Barclays Public Limited Liability has invested 0% in ADMA Biologics, Inc. (NASDAQ:ADMA). National Bank Of America Corporation De invested in 5,188 shares. 23,568 are owned by Bluecrest.

Since June 8, 2018, it had 5 insider buys, and 0 sales for $744,504 activity. 52,302 shares were bought by Grossman Jerrold B, worth $250,004 on Friday, June 8. RICHMAN ERIC I had bought 5,230 shares worth $24,999. Grossman Adam S bought 73,222 shares worth $350,001. Guiheen Lawrence P. also bought $95,600 worth of ADMA Biologics, Inc. (NASDAQ:ADMA) shares.

The stock of Adma Biologics Inc (NASDAQ:ADMA) registered an increase of 6.17% in short interest. ADMA’s total short interest was 192,800 shares in June as published by FINRA. Its up 6.17% from 181,600 shares, reported previously. With 72,900 shares average volume, it will take short sellers 3 days to cover their ADMA’s short positions. The short interest to Adma Biologics Inc’s float is 1.97%.

The stock increased 3.28% or $0.16 during the last trading session, reaching $5.04. About 409,235 shares traded or 124.30% up from the average. ADMA Biologics, Inc. (NASDAQ:ADMA) has risen 49.86% since June 16, 2017 and is uptrending. It has outperformed by 37.29% the S&P500.

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, makes, and intends to commercialize specialty plasma biologics for the treatment and prevention of immune deficiencies and infectious diseases. The company has market cap of $227.28 million. The Company’s lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical study for the treatment of primary immune deficiency disease. It currently has negative earnings. The firm also operates source plasma collection facilities in Norcross and Marietta, Georgia.

More notable recent ADMA Biologics, Inc. (NASDAQ:ADMA) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: vTv Swoons On Failed Alzheimer’s Trial, Regenxbio Gets FDA Fast Track For RGX-111” on June 13, 2018, also Seekingalpha.com with their article: “Rounds Report: Versartis Rallied Due To Strong Turnaround Progress” published on June 15, 2018, Globenewswire.com published: “ADMA Biologics Announces Pricing of Public Offering of Common Stock” on June 08, 2018. More interesting news about ADMA Biologics, Inc. (NASDAQ:ADMA) were released by: Seekingalpha.com and their article: “ADMA Biologics: The Right Way To Fix Manufacturing” published on June 14, 2018 as well as Nasdaq.com‘s news article titled: “ADMA Biologics Announces Closing of $40M Public Offering” with publication date: June 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: